TABLE 2.

Secondary and further efficacy end-point responses at week 12

	Patients	Adjusted response	Active versus placebo Respimat
			Adjusted difference (95% CI) mL	p-value
FEV1 AUC(0–3h) mL
Tiotropium Respimat 5 µg once daily	130	423±43	87±53 (−17–191)	0.100
Tiotropium Respimat 2.5 µg once daily	126	449±43	113±53 (9–217)	0.034
Placebo Respimat once daily	132	336±43
Peak FVC(0–3h) mL
Tiotropium Respimat 5 µg once daily	130	342±48	63±59 (−53–179)	0.285
Tiotropium Respimat 2.5 µg once daily	126	370±49	91±59 (−26–207)	0.126
Placebo Respimat once daily	132	279±48
Trough FVC mL
Tiotropium Respimat 5 µg once daily	130	200±51	55±62 (−67–177)	0.376
Tiotropium Respimat 2.5 µg once daily	126	249±52	103±62 (−19–226)	0.098
Placebo Respimat once daily	132	145±50
FVC AUC(0–3h) mL
Tiotropium Respimat 5 µg once daily	130	227±46	52±56 (−58–163)	0.355
Tiotropium Respimat 2.5 µg once daily	126	262±47	87±57 (−24–198)	0.125
Placebo Respimat once daily	132	175±45
Pre-dose morning PEF L·min−1
Tiotropium Respimat 5 µg once daily	129	28.05±4.91	17.36±6.23 (5.14–29.58)	0.005
Tiotropium Respimat 2.5 µg once daily	124	21.17±5.00	10.49±6.29 (−1.86–22.83)	0.096
Placebo Respimat once daily	131	10.69±4.87
Pre-dose evening PEF L·min−1
Tiotropium Respimat 5 µg once daily	130	21.94±4.84	17.57±6.12 (5.57–29.57)	0.004
Tiotropium Respimat 2.5 µg once daily	124	15.43±4.93	11.06±6.18 (−1.07–23.19)	0.074
Placebo Respimat once daily	131	4.37±4.80

Data are presented as n or mean±se, unless otherwise stated. Full analysis set. Adjusted for treatment, country, week, baseline, treatment-by-week interaction and baseline-by-week interaction. Common baseline mean±sd: forced expiratory volume in 1 s (FEV₁) 2525±618 mL; forced vital capacity (FVC) 3315±811 mL; pre-dose morning peak expiratory flow (PEF) 328.73±92.93 mL; pre-dose evening PEF 346.11±91.82 mL. AUC_(0–3h): area under the curve within 3 h post-dosing; FVC_(0–3h): FVC within 3 h post-dosing.